MLICM
MGNX icon

Metropolitan Life Insurance Company (MetLife)’s MacroGenics MGNX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,285
Closed -$48.4K – 1269
2024
Q1 		$48.4K Hold
3,285
– – ﹤0.01% 1422
2023
Q4 		$31.6K Hold
3,285
– – ﹤0.01% 1686
2023
Q3 		$15.3K Hold
3,285
– – ﹤0.01% 2017
2023
Q2 		$17.6K Hold
3,285
– – ﹤0.01% 2002
2023
Q1 		$23.6K Sell
3,285
-406
-11% -$2.44K ﹤0.01% 1795
2022
Q4 		$24.8K Hold
3,691
– – ﹤0.01% 1895
2022
Q3 		$12.8K Buy
3,691
+3,134
+563% +$12K ﹤0.01% 2221
2022
Q2 		$1.64K Sell
557
-3,318
-86% -$17.4K ﹤0.01% 2363
2022
Q1 		$34.1K Sell
3,875
-12,267
-76% -$135K ﹤0.01% 1811
2021
Q4 		$259K Hold
16,142
– – ﹤0.01% 1837
2021
Q3 		$338K Hold
16,142
– – ﹤0.01% 1688
2021
Q2 		$434K Buy
16,142
+1,129
+8% +$33.1K 0.01% 1607
2021
Q1 		$478K Sell
15,013
-451
-3% -$11K 0.01% 1448
2020
Q4 		$354K Hold
15,464
– – 0.01% 1588
2020
Q3 		$390K Hold
15,464
– – 0.01% 1378
2020
Q2 		$432K Buy
15,464
+6,672
+76% +$116K 0.01% 1317
2020
Q1 		$51.2K Sell
8,792
-6,162
-41% -$56K ﹤0.01% 2374
2019
Q4 		$163K Sell
14,954
-1,305
-8% -$12.9K ﹤0.01% 2052
2019
Q3 		$207K Buy
16,259
+2,421
+17% +$34.9K ﹤0.01% 1854
2019
Q2 		$235K Buy
13,838
+660
+5% +$11.3K ﹤0.01% 1794
2019
Q1 		$237K Hold
13,178
– – ﹤0.01% 1786
2018
Q4 		$167K Hold
13,178
– – ﹤0.01% 1936
2018
Q3 		$283K Hold
13,178
– – ﹤0.01% 1757
2018
Q2 		$272K Buy
13,178
+3,323
+34% +$74.8K ﹤0.01% 1732
2018
Q1 		$248K Sell
9,855
-1,879
-16% -$45.6K ﹤0.01% 1762
2017
Q4 		$223K Sell
11,734
-10,490
-47% -$196K ﹤0.01% 1852
2017
Q3 		$411K Hold
22,224
– – ﹤0.01% 1816
2017
Q2 		$389K Hold
22,224
– – ﹤0.01% 1882
2017
Q1 		$413K Hold
22,224
– – ﹤0.01% 1787
2016
Q4 		$454K Hold
22,224
– – ﹤0.01% 1799
2016
Q3 		$665K Hold
22,224
– – ﹤0.01% 1531
2016
Q2 		$600K Hold
22,224
– – ﹤0.01% 1571
2016
Q1 		$417K Hold
22,224
– – ﹤0.01% 1688
2015
Q4 		$688K Hold
22,224
– – 0.01% 1416
2015
Q3 		$476K Buy
22,224
+2,361
+12% +$74.1K ﹤0.01% 1670
2015
Q2 		$754K Buy
+19,863
New +$653K 0.01% 1483
2015
Q1 		– Sell
-15,901
Closed -$558K – 2348
2014
Q4 		$558K Hold
15,901
– – ﹤0.01% 1685
2014
Q3 		$332K Hold
15,901
– – ﹤0.01% 2001
2014
Q2 		$346K Buy
+15,901
New +$334K ﹤0.01% 2094

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s MGNX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of MacroGenics (MGNX) in Q2 2024, closing a stake of 3,285 shares — an estimated $48.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in MGNX in Q2 2014 and held it in 39 quarters. The position peaked at $754K in Q2 2015. 146 funds tracked by Wall St. Rank hold MGNX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining MacroGenics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,285 MacroGenics shares in Q2 2024, an estimated $48.4K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in MacroGenics in Q2 2014 and held it in 39 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s MacroGenics position peaked at $754K in Q2 2015.
  • 146 funds tracked by Wall St. Rank held MacroGenics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.